Kim Y B, Nikoulina S E, Ciaraldi T P, Henry R R, Kahn B B
Diabetes Unit, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA.
J Clin Invest. 1999 Sep;104(6):733-41. doi: 10.1172/JCI6928.
To determine whether the serine/threonine kinase Akt (also known as protein kinase B) is activated in vivo by insulin administration in humans, and whether impaired activation of Akt could play a role in insulin resistance, we measured the activity and phosphorylation of Akt isoforms in skeletal muscle from 3 groups of subjects: lean, obese nondiabetic, and obese type 2 diabetic. Vastus lateralis biopsies were taken in the basal (overnight fast) and insulin-stimulated (euglycemic clamp) states. Insulin-stimulated glucose disposal was reduced 31% in obese subjects and 63% in diabetic subjects, compared with lean subjects. Glycogen synthase (GS) activity in the basal state was reduced 28% in obese subjects and 49% in diabetic subjects, compared with lean subjects. Insulin-stimulated GS activity was reduced 30% in diabetic subjects. Insulin treatment activated the insulin receptor substrate-1-associated (IRS-1-associated) phosphoinositide 3-kinase (PI 3-kinase) 6.1-fold in lean, 3.7-fold in obese, and 2.4-fold in diabetic subjects. Insulin also stimulated IRS-2-associated PI 3-kinase activity 2.2-fold in lean subjects, but only 1.4-fold in diabetic subjects. Basal activity of Akt1/Akt2 (Akt1/2) and Akt3 was similar in all groups. Insulin increased Akt1/2 activity 1.7- to 2. 0-fold, and tended to activate Akt3, in all groups. Insulin-stimulated phosphorylation of Akt1/2 was normal in obese and diabetic subjects. In lean subjects only, insulin-stimulated Akt1/2 activity correlated with glucose disposal rate. Thus, insulin activation of Akt isoforms is normal in muscle of obese nondiabetic and obese diabetic subjects, despite decreases of approximately 50% and 39% in IRS-1- and IRS-2-associated PI 3-kinase activity, respectively, in obese diabetic subjects. It is therefore unlikely that Akt plays a major role in the resistance to insulin action on glucose disposal or GS activation that is observed in muscle of obese type 2 diabetic subjects.
为了确定丝氨酸/苏氨酸激酶Akt(也称为蛋白激酶B)在人体中是否会因注射胰岛素而在体内被激活,以及Akt激活受损是否会在胰岛素抵抗中起作用,我们测量了三组受试者骨骼肌中Akt亚型的活性和磷酸化水平:瘦人、肥胖非糖尿病患者和肥胖2型糖尿病患者。在基础状态(过夜禁食)和胰岛素刺激状态(正常血糖钳夹)下采集股外侧肌活检样本。与瘦人相比,肥胖受试者的胰岛素刺激的葡萄糖处置减少了31%,糖尿病受试者减少了63%。与瘦人相比,肥胖受试者基础状态下的糖原合酶(GS)活性降低了28%,糖尿病受试者降低了49%。糖尿病受试者胰岛素刺激的GS活性降低了30%。胰岛素治疗使瘦人、肥胖者和糖尿病受试者中与胰岛素受体底物-1相关(IRS-1相关)的磷酸肌醇3激酶(PI 3激酶)分别激活6.1倍、3.7倍和2.4倍。胰岛素还使瘦人受试者中与IRS-2相关的PI 3激酶活性刺激2.2倍,但在糖尿病受试者中仅刺激1.4倍。所有组中Akt1/Akt2(Akt1/2)和Akt3的基础活性相似。胰岛素使所有组中的Akt1/2活性增加1.7至2.0倍,并倾向于激活Akt3。肥胖和糖尿病受试者中胰岛素刺激的Akt1/2磷酸化正常。仅在瘦人受试者中,胰岛素刺激的Akt1/2活性与葡萄糖处置率相关。因此,尽管肥胖糖尿病受试者中与IRS-1和IRS-2相关的PI 3激酶活性分别降低了约50%和39%,但肥胖非糖尿病和肥胖糖尿病受试者肌肉中Akt亚型的胰岛素激活是正常的。因此,Akt不太可能在肥胖2型糖尿病受试者肌肉中观察到的对胰岛素作用于葡萄糖处置或GS激活的抵抗中起主要作用。